Coming Soon

Languages

Current Studies

Title Condition Inclusion Criteria Location Description
A prospective, open label research study to evaluate the effectiveness of lovidia hunger control formula in combination with alternate-day calorie restriction on weight management and metabolic health over 13 weeks Type 1 Diabetes, Type 2 Diabetes Weight < 300 pounds; Read, write and speak English; Desire to lose at least 20 pounds Escondido

A prospective, open label research study to evaluate the effectiveness of lovidia hunger control formula in combination with alternate-day calorie restriction on weight management and metabolic health over 13 weeks

Prominent pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes Type 2 Diabetes Diagnosed with Type 2 DM more than 12 weeks; Fasting TG ≥200 mg/dL <500 mg/dL; HDL-C ≤40 mg/dL; HbA1c ≥ 6.5% Escondido

The primary scientific aim of the PROMINENT study is to assess whether treatment with pemafibrate, will prevent myocardial infarction (MI), ischemic stroke, unstable angina requiring unplanned revascularization, and cardiovascular (CV) death in adults with type 2 diabetes (T2D) who have elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels and are at high risk for future CV events.

A New Drug Study for Patients with Type 2 Diabetes Type 2 Diabetes Have with Type 2 DM; A1c >7%- >10% ; Currently treated with diet and exercise and on Metformin at a stable dose of ≥1500mg/day for at least 12 weeks prior to enrollment Escondido

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Stagliflozin Added to Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

A 52-week study for patients with Diabetes Type 1 Type 1 Diabetes HbA1c must be 7.5% to 10.0% at screening Escondido

A 52 week phase 3, randomized, double-blind, placebo-controlled, parallel-group, efficacy, safety and tolerability trial of once daily, oral doses of an experimental drug in patients with Type 1 Diabetes Mellitus

Adult Sensor Study Type 1 Diabetes, Type 2 Diabetes Participants have been diagnosed with insulin requiring diabetes for at least 1 year. Escondido

A study to evaluate the performance of a sensor to support a full 168 hours of use.

Family History Diabetes Study Type 1 Diabetes Relative with diabetes Escondido

If you have a relative with diabetes this study will see if there are markers for higher risk of developing diabetes.

Sensor Study Type 1 Diabetes, Type 2 Diabetes At least 1 year diagnosis of DM 1 or DM 2; must be on insulin Escondido

A 10 day sensor wear study to collect data on the performance of a new continuous glucose monitoring sensor. Patients must be able to participate in 3 - 3 hour fingerstick monitoring in-clinics, be able to wear 4 sensors at one time and be able to provide medical records confirming diagnosis of diabetes >1 year

A 52-Week Study to Assess the Clinical Health Outcome of an Experimental Drug Type 2 Diabetes DM 2 > 1year; HbA1c ≥8.0 – ≤ 11.0% Escondido

A 52 week randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of an experimental drug compared to commercially available basal insulin’s for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes mellitus

Pediatric Sensor Study Type 1 Diabetes Insulin requiring diabetes Escondido

A study to evaluate the performance of two sensors in pediatric patients with insulin requiring diabetes.

Blood Glucose Meters Type 1 Diabetes, Type 2 Diabetes Escondido

Help us test new glucose meters

Continuous Glucose Monitors Type 1 Diabetes Escondido

Help us test new continuous glucose monitors. You would typically wear an investigational device for 1 to 2 weeks and be compensated based on your time.

Insulin Pump Type 1 Diabetes Escondido

Help us test new insulin pumps and pump features. You will be compensated based on your time.

A 52-week Diabetes Type 2 Study Type 2 Diabetes HbA1c 8 – 11% Escondido

A 52 week randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of an experimental drug compared to commercially available basal insulin’s for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes mellitus